Member Info for Spodulike

The few sellers are most likely selling at a loss. MMs licking their lips.

£66k buy at 3p, must be thinking wtf. Not even a converted sell off to warrant a 50% drop.

Definitely agree this drop this week as been orchestrated, not really many sells all week. But MMs need to fill those large buy orders.

This report was issued when the mcap was £7.5m only 5 months ago, so really struggling to understand why the mcap has reduced by 66% on no bad news only good actually.

"Industry interest in developing STAT-6 inhibitors

There is considerable industry interest in STAT-6 targeting treatments in the immunology space. In 2023, Sanofi (SNA.EP) struck a deal with Recludix (Private) to licence a preclinical program targeting STAT-6. The deal came with a US$125m upfront payment and potential milestone payments totalling $1.2bn. The recent in vitro study generated by the Group is similar to studies conducted by Recludix. "

6th November 2024

Strange when there’s a gap formed, mms will always try to close it. Hopefully that’s done and we can move up now.

PJ, like i've been saying for the past 3 days, MMs have sold shares they have not got, they need a lot of sellers which they haven't had.

PJ I don't think pimp realises we have a macp of only £2.5m. If we had a mcap of around £20m he may have a point to sum extent. LOL

So 4 bagger just for that deal not including milestones moving forward. Wow multi bagging soon.

Roquefort Therapeutics CEO Ajan Reginald commented:

"The granting of this Japan patent for MK cell therapy highlights both the quality of our intellectual property and the novelty of the MK cells together with the enhanced commercial opportunity in Japan. The granted patent creates the opportunity for the Company to out-license the MK cell rights for the territory of Japan to a Japanese Big Pharma company. Japan is the most sophisticated cell therapy market, with a high number of potential partners and an appealing accelerated pathway to market. The Roquefort Therapeutics Board has the personal experience and a strong network from completing deals with Japan Big Pharma. We have initiated these discussions and will update the market in due course"

'There is a two-fold commercial significance to the granting of the MK cell patent in Japan. Firstly, the Japan patent enables the opportunity to licence the MK cells to Japan Big Pharma companies for the Japan market alone, where the Roquefort Therapeutics' Board has extensive experience of working and partnering (including with Big Pharma companies such as Daiichi Sankyo, Astellas and Chughai).'

From Sept 24 RNS.

Other licensing deals and sales being worked on for the STAT6 and MK Cell Therapy. This certainly shouldn't be anywhere near £2.5m mcap. This should be nearer £10m mcap moving towards £40m mcap this year.

Https://youtu.be/3FTpl4GWDco

From Feb.

Nice

MMS will have to leave this go at some stage. Depends if all the large buy orders are filled I suppose.

Sales agreements of nearly £20m values the company around this irrespective of how the make up of payments is and that’s not including other assets. Major rerate soon. Mcap of £2.5m is totally undervalued. GLA

Blue day come on. Massive delayed buys. GLA

As pimpky is even alluding to a possible up front payment of £2m on just one deal, that’s a bagger on its own not including royalties moving forward. This should be closer to £10m mcap now.

Hopefully we should see a nice rise over 2p today after all these large delayed buys going through. We all know where this is heading. GLA

Miah, if that company has dissolved, that company hasn’t got the shares, it’s passed to the crown.

Sounds plausible if selling, but those delayed trades are mostly buys.